Zydus Cadila May Seek Emergency Use Authorization for Covid-19 Vaccine

Zydus Cadila Covid-19 Vaccine

Zydus Cadila reportedly may consider seeking a EUA (Emergency Use Authorization) for the company’s Covid-19 vaccine based on DNA-plasmid technology from the country’s drug regulator. The novel product would be the world’s maiden DNA-plasmid vaccine, if approved.


The vaccine could also be the country’s maiden vaccine for children in12 the years-and-plus age group as Zydus Cadila has initiated trials on the age group. The country already has three Covid vaccines—Covishield from Serum Institute, Covaxin from Bharat Biotech, and SputnikV from DRL.

After Bharat Biotech’s Covaxin, ZyCoV-D is the second indigenous vaccine that is a three-dose vaccine to be inoculated at days 0, 28, and 56. The company has also said that it is working on a two-jab regimen of the vaccine.


Follow and connect with us on Facebook, Twitter, LinkedIn, Elets video

Eletsonline News

Follow us on

Most Popular

200000+ Subscribers read it every day.
Subscribe Newsletter
To Top